SCHEDULE: Venrock Group Maintains 5.4% Stake in Enliven Therapeutics
Beneficial Ownership Disclosure
A group of Venrock entities and individuals reported a continued beneficial ownership of 5.4% in Enliven Therapeutics, Inc. as of September 30, 2025.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh collectively reported beneficial ownership of 3,226,331 shares of Enliven Therapeutics, Inc. common stock.
- This aggregate ownership represents 5.4% of the company's outstanding common stock.
- The percentage is based on 59,235,547 shares of common stock outstanding as of July 31, 2025, as reported in Enliven Therapeutics' Quarterly Report on Form 10-Q filed on August 13, 2025.
- The shares are held across three primary entities: VHCP III (704,336 shares), VHCP Co-Investment III (70,454 shares), and VHCP EG (2,451,541 shares).
- VHCP Management III, LLC serves as the general partner of VHCP III and the manager of VHCP Co-Investment III.
- VHCP Management EG, LLC is the general partner of VHCP EG.
- Nimish Shah and Bong Koh are the voting members of both VHCP Management III and VHCP Management EG, thereby sharing voting and dispositive power over the reported shares.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or operations.
Industry Context
This Schedule 13G filing indicates a significant, but not controlling, stake held by a prominent healthcare-focused investment group in Enliven Therapeutics, a biotechnology company. Such filings are routine disclosures for institutional investors crossing certain ownership thresholds and provide transparency into major shareholder positions within the industry.
Related Party Transactions
- The reporting persons form a group for the purposes of this Schedule 13G, with various Venrock entities and individuals (Nimish Shah and Bong Koh) sharing voting and dispositive power over the reported shares through their roles in the management entities.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, indicating continued confidence or strategic interest from a major healthcare investment group.
- Management: Awareness of a substantial shareholder group that could influence corporate governance decisions, particularly concerning nominations under Rule 14a-11.
Key Dates
| Date | Description |
|---|---|
| 2023-03-13 | Date of Power of Attorney for Nimish Shah and Bong Koh, and Joint Filing Agreement (incorporated by reference). |
| 2025-07-31 | Date as of which 59,235,547 shares of common stock were outstanding, as reported by the Issuer. |
| 2025-08-13 | Date Enliven Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, reporting outstanding shares. |
| 2025-09-30 | Date of event which requires filing of this statement, representing the 'as of' date for beneficial ownership. |
| 2025-11-14 | Signature date of the Schedule 13G Amendment No. 3 filing. |
Keywords
Enliven Therapeutics, Venrock Healthcare Capital Partners, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.